🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →
S&P 500: 754.37 -0.4% NASDAQ 100: 679.89 -1.2% Dow Jones: 534.08 -0.5%

Decheng Capital - Q3 2026 13F Filings

DE

Decheng Capital LLC

CIK: 0002010850
Address: California Menlo Park 3000 Sand Hill Rd Building 2, Suite 110
$685.07 M
Portfolio Value
11
Assets Held
Reporting Period: Q3 2026
Filing Status:
Active
Last Updated: 11/13/2026

Portfolio Summary (Q3 2026)

View Full Portfolio Analysis

Top Buys

Q3 2026

No buy transactions available for this period

Top Sells

Q3 2026
1. RVMD Revolution Medicines
−$9.86 M
2. NAMS Newamsterdam Pharma Company Nv
−$5.99 M
3. RCUS Arcus Biosciences
−$1.03 M
4. TNGX Tango Therapeutics
−$625,200
5. BYSI Beyondspring
−$565,950.11

Asset Allocation

Stocks/ETFs
-6.38%
$685.07 M 100.00%
Options
$0 0.00%
Debt
$0 0.00%
Other
$0 0.00%

Sector Allocation (Stocks)

Decheng Capital Q3 2026 Filing Summary

Decheng Capital LLC filed its 13F report for Q3 2026 on November 13, 2026. The portfolio totaled 685.07 M reflecting a -6.38% change from the prior quarter, spanning 11 assets. The top 10 holdings comprised 99.9% of the portfolio, with Financials as the largest sector allocation. Quarterly activity included 0 new positions and 3 complete exits.

Report Type

Status

Data Summary

Items:

Total Value:

Actions

Issuer Name Class Value Shares Option Type

FAQs for Decheng Capital’s Q3 2026 Filing

Decheng Capital submitted their Form 13F-HR for the Q3 2026 period on 11/13/2026. This was the only submission for the quarter.

In the Q3 2026 filing, Decheng Capital reported a managed portfolio value of 685.07 M, consisting of 11 individual positions.

This page displays the raw filing documents. To see which stocks Decheng Capital bought or sold during Q3 2026, please visit Decheng Capital's Portfolio Analysis page.